

SciClone Pharmaceuticals

[View the current SciClone Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bioporcorporate/9229-SciClone+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bioporcorporate/9229-SciClone+Pharmaceuticals.html>)

Contact Details:

901 Mariner's Island Boulevard, Suite 205

San Mateo

CA

94404

United States of America

Tel: 650 358 3456

Fax: 650 358 3469

Email: investorrelations@sciclone.com

SciClone is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases, such as hepatitis B, hepatitis C, cancer, immune system disorders and cystic fibrosis.

Recent Publications by SciClone Pharmaceuticals:



- [Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing.](#)
*SciClone Pharmaceuticals licensed the commercial and patent rights to...*28th December, 2007
SciClone Pharmaceuticals, Inc., 901 Mariner's Island Blvd., San Mateo, CA- Ann N Y Acad Sci. 2007 Sep;1112:351-6. ([DOI Direct Link](#))
- [Comparison of assays for determination of peptide content for lyophilized thymalfasin.](#)
*Precise determination of the peptide content in drug substance samples...*3rd August, 2005
SciClone Pharmaceuticals, Inc., 901 Mariner's Island Blvd, San Mateo, CA- J Pept Res. 2005 Apr;65(4):433-9. ([DOI Direct Link](#))
- [Quantitative analysis of thymosin alpha1 in human serum by LC-MS/MS.](#)
*A high performance liquid chromatography with tandem mass spectrometry...*11th February, 2004
SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd., San Mateo, CA- AAPS PharmSciTech. 2000 May 14;1(2):E11. ([DOI Direct Link](#))

Press Releases on SciClone Pharmaceuticals:

Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter	23rd November, 2009	Transcept Pharmaceuticals, Inc.	<i>POINT RICHMOND, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy</i>
NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options	23rd November, 2009	National Comprehensive Cancer Network	<i>SAN FRANCISCO, Nov. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals (Nasdaq: PARD) today announced the sale of 3,465,878 of its common shares to Azimuth Opportunity Ltd. for gross proceeds of</i>
Poniard Announces \$7.4 Million Financing	23rd November, 2009	Poniard Pharmaceuticals	<i>CAMBRIDGE, Mass., Nov. 23 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced the appointment</i>
Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman	23rd November, 2009	Ligon Discovery, Inc.	<i>NASHVILLE, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced positive new top-line results from a study evaluating the safety and efficacy of</i>
Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients	23rd November, 2009	Cumberland Pharmaceuticals Inc.	

BioNews Results for SciClone Pharmaceuticals



- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Genetic Engineering News: Nov 15 2009 6:06PM Matching: sciclone pharmaceuticals
- [Stocks That Stand Out For Nov. 13th, 2009 Are HRRN, SCLN, HEPH, CYTK](#)

- Pharmacy Choice: Nov 14 2009 6:39AM Matching: sciclone pharmaceuticals*
- [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Freshnews.com: Nov 13 2009 12:29AM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Individual.com: Nov 13 2009 12:13AM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Down 20.7% Since SmarTrend's Sell Recommendation](#)
Individual.com: Nov 12 2009 7:56AM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Down 20.7% Since SmarTrend's Sell Recommendation](#)
TradingMarkets: Nov 12 2009 3:54AM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Market Wire: Nov 12 2009 9:54PM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Reuters: Nov 12 2009 10:17PM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
[Compound's Anti-Cancer Properties Highlighted at](#)
PR inside: Nov 12 2009 10:13PM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
[Compound's Anti-Cancer Properties Highlighted at](#)
PR inside: Nov 12 2009 10:11PM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data](#)
Market Wire via MSN Money: Nov 12 2009 9:46PM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Stockwatch: Nov 12 2009 9:42PM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Yahoo! Canada: Nov 12 2009 10:16PM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
NewsBlaze: Nov 12 2009 9:50PM Matching: sciclone pharmaceuticals
 - [SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings](#)
Marketwire via Yahoo!/: Nov 12 2009 9:43PM Matching: sciclone pharmaceuticals

SciClone Pharmaceuticals Clinical Trials:



- [Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine](#)

SciClone Pharmaceuticals Patents:



- 7297676- [Thymosin alpha 1 peptide/polymer conjugates](#)

- 5849696- [Composition and method of treating hepatitis C](#)
- 5939423- [Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir](#)
- 6001799- [Method of treating hepatitis C in non-responders to interferon treatment](#)
- 6200952- [Combination therapy method for treating chronic hepatitis B](#)
- 6262230- [Analogues of thymosin .alpha.1](#)
- 6288033- [Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir](#)
- 6462017- [Method of reducing side effects of chemotherapy in cancer patients](#)
- 6495521- [Combination therapy method for treating chronic hepatitis B](#)
- 7173013- [Treatment of tuberculosis using immunomodulator compounds](#)
- 7208167- [Treatment of hepatitis C with thymosin and peptide combination therapy](#)
- 5308833- [Method for treating hepatitis B carriers with minimal disease](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

